Procter & Gamble Health (BOM:500126) WACC %:9.15% (As of Jul. 19, 2026) — 14% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:500126 Procter & Gamble Health Ltd BOM:500126
86 GF Score
Price ₹6,797.90
GF Value ₹6,049.27
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Procter & Gamble Health WACC %?

Procter & Gamble Health BOM:500126 -0.76% 86 WACC % is 9.15% as of Jul. 19, 2026, which is 14% below its 10-year median of 10.62. GuruFocus rates BOM:500126 with a GF Score™ of 86/100 and a GF Value™ of ₹6,049.27 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 1,021 Drug Manufacturers companies, Procter & Gamble Health ranks worse than 51.42% on this metric.

As of today (2026-07-19), Procter & Gamble Health's weighted average cost of capital is 9.15%%. Procter & Gamble Health's ROIC % is 74.38% (calculated using TTM income statement data). Procter & Gamble Health generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.

For a comprehensive WACC calculation, please access the WACC Calculator.


Procter & Gamble Health  (BOM:500126) WACC % Explanation

Because it costs money to raise capital. A firm that generates higher ROIC % than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Procter & Gamble Health's weighted average cost of capital is 9.15%%. Procter & Gamble Health's ROIC % is 74.38% (calculated using TTM income statement data). Procter & Gamble Health generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Be Aware

1. GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding latest one-year quarterly average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together.
For companies that report quarterly, GuruFocus combines all of the most recent year's quarterly debt data from the beginning of the year to the year-end and calculates the average.
For companies that report semi-annually, GuruFocus combines all of the most recent year's semi-annual debt data from the start of the year to the year-end and calculates the average.
For companies that report annually, GuruFocus combines the beginning and ending annual debt data from the most recent year and then calculates the average.

2. The WACC formula discussed above does not include Preferred Stock. Please adjust if preferred stock is considered.

3. (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.

4. GuruFocus uses the latest TTM Interest Expense divided by the latest one-year quarterly average debt to get the simplified cost of debt.


Related Terms

Procter & Gamble Health WACC % Historical Data

* Premium members only.

The historical data trend for Procter & Gamble Health's WACC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Procter & Gamble Health WACC % Chart

Procter & Gamble Health Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Jun21 Jun22 Jun23 Jun24
WACC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.76 10.95 11.34 10.32 8.25

Procter & Gamble Health Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
WACC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.87 0.00 8.57 0.00 9.29

BOM:500126 vs ZTS, UTHR: WACC % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Procter & Gamble Health's WACC %, along with its competitors' market caps and WACC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Procter & Gamble Health WACC % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Procter & Gamble Health's WACC % distribution charts can be found below:

* The bar in red indicates where Procter & Gamble Health's WACC % falls into.


BOM:500126
86GF Score
Procter & Gamble Health Ltd BOM:500126
WACC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Procter & Gamble Health WACC % Calculation

The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. The WACC is commonly referred to as the firm's cost of capital. Generally speaking, a company's assets are financed by debt and equity. WACC is the average of the costs of these sources of financing, each of which is weighted by its respective use in the given situation. By taking a weighted average, we can see how much interest the company has to pay for every dollar it finances.

WACC=E/(E + D)*Cost of Equity+D/(E + D)*Cost of Debt*(1 - Tax Rate)

1. Weights:
Generally speaking, a company's assets are financed by debt and equity. We need to calculate the weight of equity and the weight of debt.
The market value of equity (E) is also called "Market Cap". As of today, Procter & Gamble Health's market capitalization (E) is ₹112840.939 Mil.
The market value of debt is typically difficult to calculate, therefore, GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding the latest one-year quarterly average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together. As of Mar. 2026, Procter & Gamble Health's latest one-year quarterly average Book Value of Debt (D) is ₹77.45 Mil.
a) weight of equity = E / (E + D) = 112840.939 / (112840.939 + 77.45) = 0.9993
b) weight of debt = D / (E + D) = 77.45 / (112840.939 + 77.45) = 0.0007

2. Cost of Equity:
GuruFocus uses Capital Asset Pricing Model (CAPM) to calculate the required rate of return. The formula is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
a) GuruFocus uses 10-Year Treasury Constant Maturity Rate as the risk-free rate. It is updated daily. The current risk-free rate is 7.02%. Please go to Economic Indicators page for more information. Please note that we use the 10-Year Treasury Constant Maturity Rate of the country/region where the company is headquartered. If the data for that country/region is not available, then we will use the 10-Year Treasury Constant Maturity Rate of the United States as default.
b) Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. Procter & Gamble Health's beta is 0.3549.
c) (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
Cost of Equity = 7.02% + 0.3549 * 6% = 9.1494%

3. Cost of Debt:
GuruFocus uses latest TTM Interest Expense divided by the latest one-year quarterly average debt to get the simplified cost of debt.
As of Mar. 2026, Procter & Gamble Health's interest expense (positive number) was ₹5.5 Mil. Its total Book Value of Debt (D) is ₹77.45 Mil.
Cost of Debt = 5.5 / 77.45 = 7.1014%.

4. Multiply by one minus TTM Tax Rate:
GuruFocus uses the most recent TTM Tax Expense divided by the most recent TTM Pre-Tax Income to calculate the tax rate. The calculated TTM tax rate is limited to between 0% and 100%. If the calculated tax rate is higher than 100%, it is set to 100%. If the calculated tax rate is less than 0%, it is set to 0%.
The latest calculated TTM Tax Rate = 1229.5 / 4498.6 = 27.33%.

Procter & Gamble Health's Weighted Average Cost Of Capital (WACC) for Today is calculated as:

WACC=E / (E + D)*Cost of Equity+D / (E + D)*Cost of Debt*(1 - Tax Rate)
=0.9993*9.1494%+0.0007*7.1014%*(1 - 27.33%)
=9.15%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about WACC % →
What does a WACC % of 9.15% mean?
Procter & Gamble Health (BOM:500126) has a WACC % of 9.15% as of Jul. 19, 2026. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on Procter & Gamble Health and its competitors. This is 14% below median its historical median of 10.62. Over the past decade, Procter & Gamble Health's WACC % has ranged from 7.64 to 14.76. According to the industry distribution chart, Procter & Gamble Health ranks #525 out of 1021 companies in the Drug Manufacturers industry, placing it in the top 51.4%.
Is Procter & Gamble Health's WACC % too high?
Procter & Gamble Health's current WACC % of 9.15% is 14% below median its 10-year median of 10.62. Over the past 10 years, this metric has ranged from a low of 7.64 to a high of 14.76. The Drug Manufacturers industry median WACC % is 8.99. Procter & Gamble Health's value of 9.15% is 1.8% above this industry median. Based on the distribution chart, Procter & Gamble Health ranks #525 out of 1021 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Procter & Gamble Health has a GF Score™ of 86/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Procter & Gamble Health's WACC % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Procter & Gamble Health ranks #525 out of 1021 companies for WACC %. This places Procter & Gamble Health in the lower half of its industry. The industry median WACC % is 8.99. Procter & Gamble Health's value of 9.15% is 1.8% above this benchmark. Historically, Procter & Gamble Health's own WACC % has ranged from 7.64 to 14.76 over the past decade. While the company's 10-year median is 10.62 vs. the industry median of 8.99, Procter & Gamble Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good WACC % for a Drug Manufacturers company?
The median WACC % among Drug Manufacturers companies is 8.99, based on 1,021 companies in the industry. Companies in the top quartile (top 25%) have a WACC % significantly above this median, while those in the bottom quartile fall well below. However, WACC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Procter & Gamble Health's current WACC % of 9.15% is 1.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high WACC % mean?
A high WACC % can signal that a stock is expensive relative to its fundamentals. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on Procter & Gamble Health and its competitors. For the Drug Manufacturers industry, the median WACC % is 8.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Procter & Gamble Health's current WACC % is 9.15%, which is 14% below median its own 10-year median of 10.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Procter & Gamble Health stock overvalued right now?
Based on GuruFocus' analysis, Procter & Gamble Health (BOM:500126) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹6,049.27, compared to a current price of ₹6,797.90 — trading 12.4% above its estimated fair value. The current WACC % is 9.15%, which is 14% below median its 10-year median of 10.62 and 1.8% above the Drug Manufacturers industry median of 8.99. Procter & Gamble Health's overall GF Score™ is 86/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is WACC % calculated?
WACC % is calculated from a company's financial statements. For Procter & Gamble Health (BOM:500126), the current WACC % is 9.15% as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Procter & Gamble Health (BOM:500126) Overvalued in 2026?

Based on GuruFocus' analysis, Procter & Gamble Health stock appears to be overvalued. The current stock price of ₹6,797.90 is trading 12.4% above its estimated GF Value™ of ₹6,049.27. GuruFocus considers Procter & Gamble Health to be Modestly Overvalued.

Key valuation signals for BOM:500126:

  • WACC %: 9.15% (14% below median its 10-year median of 10.62)
  • GF Value™: ₹6,049.27 vs. price of ₹6,797.90 (12.4% above fair value)
  • GF Score™: 86/100 with 6 warning signs
  • Industry Position: 1.8% above the Drug Manufacturers median (#525 of 1021)

No single metric tells the full story. See the BOM:500126 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Procter & Gamble Health Business Description

Other Exchanges PGHL:India
Address Cardinal Gracias Road, Ground Floor And First Floor, P&G Plaza, Chakala, Andheri East, Mumbai, MH, IND, 400099
Procter & Gamble Health Ltd is an India based pharmaceutical company engaged in manufacturing and selling of healthcare products, viz., vitamins, minerals and supplements. Patients are end consumers of the products. The Company's distribution channels (direct & indirect), inter alia, include distributors, health care professionals, pharmacies and chemists. Cosome, Evion, Neurobion, Nasivion, Polybion, Livogen and Seven Seas are some of the brands of the company. The geographical segments include sales in India and exports.
86GF Score

Get the complete analysis for BOM:500126

WACC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹6,797.90
Price
₹6,049.27
GF Value